NICE(UK): Durvalumab with tremelimumab can be used, within its marketing authorisation, as an option for untreated advanced or unresectable hepatocellular carcinoma (HCC) in adults. Durvalumab with tremelimumab can… read more.
In a preclinical study, researchers found tamoxifen encourages uterine cell growth; the findings could change how some breast cancers are treated in the future Studies show that people… read more.
BeOne Medicines Ltd. announced that the European Commission has approved a new film-coated tablet formulation of Brunkinsa (zanubrutinib) for all approved indications. “Developed to meet the real-world needs… read more.
Thanks to new advances in cancer care, more and more people are surviving cancer, with a projected total of 22.5 million survivors by 2032. The need for proper… read more.
Catalyst Pharmaceuticals, Inc. announced the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Small Cell Lung Cancer (SCLC) now include new additions involving Lambert Eaton… read more.
Boehringer Ingelheim’s Hernexeos (zongertinib tablets) has been approved by the FDA. The kinase inhibitor is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small… read more.
Cancer care charity, Maggie’s, provides tailored support for cancer patients that complements clinical treatment. Founded in 1996 by Maggie Keswick-Jencks after she was told that she had recurrent… read more.
Pfizer Inc. announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the… read more.
AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL)… read more.
Roche announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for… read more.
About one quarter of patients with muscle-invasive bladder cancer (MIBC) may be treated and derive a benefit with the current standard chemotherapy. To better understand why some tumors… read more.
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer (NSCLC) at… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
